103 articles - From Friday Feb 07 2025 to Friday Feb 14 2025
Guidelines and related publications, position statements, white papers, technical reviews, consensus statements, etc…
| Gastroenterology |
|---|
meta-analyses and systematic reviews
| Am J Gastroenterol |
|---|
Effect of Glucagon-Like Peptide-1 Receptor Agonists on Bowel Preparation for Colonoscopy: A Systematic Review and Meta-Analysis. Furthermore, the mean BBPS score was lower in the GLP1-RAs group compared to the control group (MD -0.34; 95% CI -0.51, -0.17; p=0.0001). Our findings suggest that using GLP-1RA increases the risk of inadequate bowel preparation. |
RCT, clinical trials, retrospective studies, etc…
| Aliment Pharmacol Ther |
|---|
Challenges in Histological Endpoints for MASH Therapies: An Exercise in Statistical Modelling. Imprecise histologic scoring disproportionately impacts the 'superior' arm as the error is proportional to the true response rate. This dilution of effect size should be considered when weighing the clinical benefit and the overall risk-benefit profile in the review of NASH studies. This argues for the adoption of non-invasive biomarkers rather than histologic endpoints. |
Clinical Trial to Assess the Safety and Tolerability of Anti-IL 23 Monoclonal Antibody Guselkumab in Patients With Alcohol-Associated Liver Disease. Guselkumab is safe in doses up to 100 mg and may reduce inflammation markers in ALD. These findings support further phase 2 studies to evaluate the efficacy of guselkumab in ALD, particularly in patients with severe phenotypes. |
Prevalence and Predictors of Suspected Metabolic Dysfunction-Associated Steatotic Liver Disease in Adolescents in the United States. Most adolescents with elevated ALT met MASLD criteria, yet a portion lacked cardiometabolic risk factors or other identifiable causes. These results support the adoption of MASLD criteria in adolescents while indicating a need for further research into cryptogenic ALT elevation in paediatric populations. |
Risk of Hepatocellular Cancer in U.S. Patients With Compensated Cirrhosis Treated With Direct-Acting Antivirals Versus Interferon. The study shows a reduced risk of de novo HCC among patients with chronic HCV-related compensated cirrhosis who received DAA treatment compared to that of untreated patients. There were no differences in HCC risk between DAA-treated and IFN-treated patients. |
The Lipidomic Profile Discriminates Between MASLD and MetALD. Our findings indicate that HDL-centric lipidomic markers, particularly those within the larger and medium HDL subfraction, may differentiate MetALD from MASLD. Further longitudinal and experimental studies are warranted to validate these findings and assess their clinical implications. |
| Am J Gastroenterol |
Identifying Metabolic Dysfunction-Associated Steatotic Liver Disease Using Natural Language Processing in a US National Cohort. This algorithm identified 299,259 (36.5%) of the study cohort with MASLD, compared with 23,218 patients (2.8%) identified using International Classification of Diseases-9/10 codes. An algorithm combining rule-based NLP with cardiometabolic risk factors and alcohol use from EHRs accurately identifies and classifies SLD and can be applied in large epidemiologic studies of SLD in the Veterans Health Administration. |
Inflammatory Bowel Disease, Periconceptional Disease Activity, and Risk of Major Congenital Anomalies: A Nationwide Cohort Study. Children of women with IBD had a heightened susceptibility to mCAs, although absolute and relative risks were lower than previously reported. IBD activity was not linked to mCA risks, but those analyses included relatively few events. |
Risk of Post-polypectomy Bleeding After Colorectal Endoscopic Mucosal Resection in Patients With Cirrhosis: A Propensity-Matched Analysis of the US Collaborative Network. Optimizing patients with cirrhosis, especially with decompensated disease, before colorectal EMR and monitoring for post-procedure bleeding remain important. A conservative, supportive approach to managing bleeding in patients with cirrhosis may be as effective as in those without cirrhosis. |
Spatiotemporal Study of a Risk-Stratification Epigenetic-Based Biomarker Assay in Barrett's Esophagus Patients. Esopredict showed high predictive performance in multiple spatiotemporal samples in BE patients. These data further support the use of Esopredict as a robust test to distinguish high-risk BE patients, who may benefit from endoscopic eradication therapy or increased surveillance frequency, from low-risk patients, who may be candidates for less frequent surveillance and non-interventive observation. |
Spray and forced coagulation mode endoscopic submucosal dissection for early gastric neoplasms: a multicenter randomized controlled trial. SCM-ESD is a promising technique that may streamline ESD by eliminating the need to exchange devices and reducing costs. (UMIN Clinical Trials Registry, Numbers: UMIN000047353). |
| Clin Gastroenterol Hepatol |
Proteomics guided biomarker discovery, validation, and pathway perturbation in infection-related acute decompensation of cirrhosis. The study identifies novel protein signatures and pathways linked with infections in AD. A biomarker guided treatment of infections can limit unnecessary antimicrobials use and the burden of drug-resistance in cirrhosis. |
| Endoscopy |
Outcomes after radical endoscopic resection of high-risk T1 esophageal adenocarcinoma: an international multicenter retrospective cohort study. Our findings present low rates of LNM after radical ER of high-risk T1 EAC, consistent with other endoscopy-focused studies. Post-surgical patients are still at risk for metastasis and disease-specific mortality. These results suggest that endoscopic surveillance is suitable for selected cases, but further prospective studies are needed to refine patient selection and confirm optimal outcomes. |
Portal versus peripheral circulating tumor cells as prognostic biomarkers in patients with stage I-III pancreatic ductal adenocarcinoma. Higher CTC counts in both portal and peripheral systems were significantly associated with poorer survival in stage I-III PDAC; however, only portal CTCs reflected tumor aggression and loco-regional metastasis. |
The development and ex-vivo evaluation of a computer-aided quality control system for Barrett's esophagus endoscopy. This study presents the first CAQ system for automated quality control in BE. The system effectively distinguishes poorly from well-visualized mucosa and enhances neoplasia detection when integrated with CADe. |
| Gastroenterology |
Burden and Cost of Gastrointestinal, Liver, and Pancreatic Diseases in the United States: Update 2024. GI diseases are responsible for a considerable and growing burden of health care use and costs. Funding innovative GI science and supporting the practice of GI medicine are critical to meeting the burden of GI illness. |
Overlap of Genomic and Transcriptomic Genes Identified in Familial Eosinophilic Esophagitis. Genes related to immune response, barrier dysfunction, and cell adhesion were identified in familial EoE cases and unaffected family members, supporting a genetic familial predisposition and a possible multi-hit background to disease pathophysiology. |
Risk of gastric adenocarcinoma after eradication of Helicobacter pylori. This study revealed a decreasing incidence of gastric non-cardia adenocarcinoma after Helicobacter pylori eradication treatment in five Western populations. The risk became virtually similar to the background population from 11 years after treatment. |
The Moonlighting Function of GLS2 Promotes Immune Evasion of Pancreatic Ductal Adenocarcinoma by TTLL1-mediated YAP1 Glutamylation. Furthermore, GLS2-K151 acetylation and YAP1 E100 glutamylation levels correlated positively with PD-L1 expression and poor prognosis in PDAC patients. The present study revealed a novel mechanism by which hypoxia upregulates PD-L1 expression and highlighted the involvement of GLS2 in non-canonical metabolic pathways involved in tumour immune evasion, with implications for PDAC treatment. |
| Gastrointest Endosc |
Endoscopist adenoma detection rate associated with neoplasia detection during subsequent-round colonoscopy in fecal immunochemical test-based colorectal cancer screening: cross-sectional analysis of the SCREESCO randomized controlled trial. The impact of endoscopists' ADRs on ACN detection in subsequent-round colonoscopies underscores the importance of considering ADR for optimal follow-up after first-round colonoscopy in a FIT-based screening program. |
Ergonomic Impact of an Automated Device for Endoscopic Tool Insertion and Transfer. These findings suggest that INSERTrument could improve the ergonomics of endoscopic procedures, potentially reducing the incidence of musculoskeletal injuries among endoscopists. Further studies are warranted to explore the long-term benefits and clinical implications of this device in routine endoscopic practice. |
Long slim versus conventional self-expandable metallic stent in bilateral endoscopic side-by-side deployment for unresectable malignant hilar biliary obstruction. The success rate of endoscopic bilateral revisionary stent insertion in LSMS group was also higher (100% vs 33.3%, P=0.000). Bilateral LSMS placement is a viable option for MHBO patients with advantages of less operative difficulty and easier future re-intervention over conventional SBS stenting. |
SURVEILLANCE FINDINGS IN HIGH-RISK PATIENTS AFTER BASELINE COMPUTER-ASSISTED DETECTION COLONOSCOPY: A PROPENSITY SCORE MATCHING ANALYSIS. Patients who had CADe use at baseline colonoscopy had significantly lower rates of metachronous lesions, including advanced adenoma, on surveillance colonoscopy. |
Safety and efficacy of endoscopic ultrasound-guided pelvic abscess drainage with lumen-apposing metal stents for complicated acute diverticulitis. EUS-PAD could be considered a safe and effective rescue strategy in case of failed or contraindicated percutaneous approach for the management of complicated AD to reduce the need for urgent surgery. Comparative data is necessary to confirm these observations. |
Thirty-day hospital admission following high-risk outpatient ERCP: incidence and analysis of risk factors based on a secondary analysis of the Stent Versus Indomethacin trial dataset. High-risk patients who undergo outpatient ERCP and are discharged home are at considerable risk for hospital admission within 30 days and have increased rate of pancreatitis and longer length of hospital stay compared to outpatients admitted to the hospital immediately following ERCP, and some factors may predict this outcome. These findings should influence decision making and informed consent when electing to proceed with high-risk ERCP, recognizing that patients with sphincter of Oddi dysfunction were over-represented in this cohort, which may limit generalizability to a typical ERCP practice. |
| Hepatology |
Aptamer-directed, nanovesicle-mediated targeting of undruggable molecules in preclinical cholangiocarcinoma models. Herein, we show that aptamer-directed, nanovesicle-mediated targeting of YAP, LCK, and tafazzin potentiates chemosensitivity in two CCA models when delivered using aptamer-guided milk-derived nanovesicles. |
Global burden of HBV-related liver disease: Primary liver cancer due to chronic HBV infection increased in over one-third of countries globally from 2000 to 2021. From 2000 to 2021, decreases in HBV-related liver disease incidence and prevalence were observed; however, more than one-third of countries showed an increase in the incidence of HBV-related PLC. These findings highlight the need for strengthened HBV treatment efforts to reduce the risk of liver cancer. |
Targeting protein hyperSUMOylation halts cholangiocarcinoma progression by impairing cancer cell viability and tumor-stroma crosstalk. Aberrant SUMOylation drives CCA progression by enhancing cell survival, proliferation, and shaping the tumor microenvironment. Targeting SUMOylation shows potential in inhibiting CCA growth, representing a promising therapeutic strategy. |
| J Hepatol |
A phase IIb randomised-controlled trial of the FFAR1/FFAR4 agonist icosabutate in MASH. Although the primary endpoint was not met, treatment with icosabutate demonstrated encouraging fibrosis (as measured by both conventional and AI-assisted digital pathology) and non-invasive biomarker data, supporting further development in MASH patients. NCT04052516 IMPACT AND IMPLICATIONS: • With expression on multiple cells types regulating both glycemic control and liver inflammation, targeting free fatty acid receptors 1 and 4 could offer an attractive approach for the treatment of both fibrosing MASH and it's comorbidities.• Although treatment of F1-F3 MASH patients with oral icosabutate (a FFAR1/FFAR4 agonist) did not meet the pre-defined primary endpoint (MASH resolution without worsening of fibrosis), the overall dataset (including AI-assisted digital pathology) suggest an improvement in fibrosis in treated patients.• Improvements in multiple biomarkers of liver damage, inflammation and glycemic control were observed in response to therapy.• Icosabutate was generally safe and well-tolerated, and the overall data support further testing of icosabutate in MASH patients, in particular those with more advanced disease (F2-F3 fibrosis) and type 2 diabetes. |
Hyodeoxycholic acid ameliorates cholestatic liver fibrosis by facilitating m<sup>6</sup>A-regulated expression of a novel anti-fibrotic target ETV4. The present study underscores ETV4 as a novel anti-fibrotic target and demonstrates that HDCA remodels ECM by facilitating m 6 A-regulated ETV4 expression, offering potential therapeutic approaches for cholestatic liver fibrosis. Impact and implications This study delves into the underlying mechanisms of cholestatic liver fibrosis and offers potential therapeutic targets. The research highlights ETV4 as a novel anti-fibrotic target and is essential for the therapeutic effects of hyodeoxycholic acid (HDCA) against cholestatic liver fibrosis. These findings are important for both the scientific community and patients with cholestatic liver diseases, offering valuable insights for future therapeutic strategies that focus on regulating m 6 A-dependent epigenetic modifications of anti-fibrotic targets like ETV4 and developing new interventions utilizing HDCA. |
Number of people treated for hepatitis C virus infection in 2014-2023 and applicable lessons for new HBV and HDV therapies. In the last 10 years, 21% of al HCV infections were treated with DAAs. Regional and temporal variations highlight the importance of active screening strategies. Without program enhancements, the number of treated PLHCV stalled in every country/region which may not reflect a lower prevalence but may instead reflect the diminishing returns of the existing strategies. Impact and implications Long-term hepatitis C virus (HCV) infection can lead to cirrhosis and liver cancer. Since 2014, these infections can be effectively treated with 8-12 weeks of oral therapies. In 2015, the World Health Organization (WHO) established targets to eliminate HCV by 2030, which included treatment targets for member countries. The current study examines HCV treatment patterns across 119 countries and regions from 2014 to 2023 to assess the impact of national programs. This study can assist physicians and policymakers in understanding treatment patterns within similar regions or income groups and in utilizing historical data to refine their strategies in the future. |
Protein phosphatase 6 regulates metabolic dysfunction-associated steatohepatitis via the mTORC1 pathway. PPP6C is directly activated by FGF21 via FGFRs/βKlotho and improves MASH features through dephosphorylation of TSC2 in hepatocytes. This study implies that pharmacological approaches, genetic or metabolic factors targeting PPP6C activity may offer attractive prospects for treating liver fibrosis and MASH. |
The Freiburg Index of Post-TIPS Survival (FIPS) identifies patients at risk for further decompensation and ACLF after TIPS. The present study reveals that the FIPS predicts development of further decompensation and ACLF after TIPS implantation. These events are responsible for impaired transplant-free survival in FIPS high-risk patients. These results pave the way for the development of tailored clinical management strategies. |
Unveiling the Molecular Legacy of Transient Insulin Resistance: Implications for Hepatic Metabolic Adaptability. Transient insulin receptor blockade also altered the liver's molecular clock, particularly affecting PPARα transcriptional responsiveness. Seemingly reversible and unnoticed metabolic challenges in early adulthood may predispose the liver to exacerbated metabolic dysfunctions when confronted with chronic challenges later in life. |
Plenty of the editorials are available as full text through the publisher website using the provided link
| Aliment Pharmacol Ther |
|---|
| Gastroenterology |
Gut Microbiome Signature in Predisease Phase of Inflammatory Bowel Disease: Prediction to Pathogenesis to Prevention. Understanding these changes in the predisease phase provides a means of predicting IBD in high-risk populations and offers insights into possible mechanisms involved in disease pathogenesis. Finally, we discuss strategies to use this information to design interventions aimed at modulating the microbiome as a means of preventing or delaying the onset of IBD. |
Immune Dysfunction and Infection Risk in Advanced Liver Disease. This review addresses key evidence supporting the paradigm of immune dysfunction as a risk for microbial infections and identifies potential therapeutic targets for intervention. The primary focus is on cirrhosis-associated immune dysfunction and alcohol-associated liver disease, because the bulk of available data are from these 2 conditions. |
| J Hepatol |
misc publications eg case reports, tools of the trade, images of the month, etc…
| Am J Gastroenterol |
|---|
| Endoscopy |
| Gastroenterology |
| Gastrointest Endosc |
| Gut |
| Hepatology |
Letters to the editors and authors’ replies
| Aliment Pharmacol Ther |
|---|
| Gut |
| J Hepatol |